BrightSpring Health Services, Inc. (BTSG) stock intrinsic value fair value estimate & owner earnings analysis

BrightSpring Health Services is a US home- and community-based healthcare company built around two businesses. Pharmacy Solutions (about $11.4 billion of 2025 revenue) dispenses drugs through two channels. Infusion and Specialty Pharmacy ($9.1 billion, up about 39% in 2025) handles expensive specialty and oncology drugs. Home and Community Pharmacy ($2.3 billion, up 5.5%) is the PharMerica long-term-care pharmacy that serves nursing homes, assisted living and group homes. Provider Services (about $1.5 billion) provides home health, hospice, rehab and primary care. In January 2025 the company agreed to sell its Community Living business (group homes and waiver programs for people with intellectual and developmental disabilities) to Sevita for $835 million. The sale closed in the first half of 2026, bringing in about $811 million of cash. This valuation covers only the business that remains. How we measured earnings. We start from reported operating cash flow and remove working-capital swings. We then deduct three items as real costs. The first is stock compensation, about $70 million a year since the January 2024 IPO. The second is bad-debt provisions ($56 million in 2025); the company adds these back as non-cash, but uncollected bills are a real cost. The third is the capital spending needed to maintain the business, roughly 0.8% of revenue, with the part that funds growth excluded. On that basis the whole company, including Community Living, earned about $309 million for shareholders in 2025, or $1.41 per share. That compares with $129 million in 2024 and a loss in 2023. The 2023 figure was depressed by a one-time $120 million settlement of the Silver whistleblower case against PharMerica, which was paid in 2024 and 2025 and dismissed with prejudice. Because debt is valued separately, we add back cash interest and remove what Community Living contributed (roughly $96 million to $115 million a year). That leaves about $397 million of cash earnings before lenders for the continuing business in 2025, up from about $250 million in 2024 on a like-for-like basis. Amortization of acquired intangibles (about $91 million a year) is added back as a sunk acquisition cost. The pharmacy customer and payer relationships it relates to have been renewed and grown through ongoing selling effort rather than replaced by further purchases, so we charge no separate decay. Starting point and near-term path. We measure from 2025, the first full year of the business in its current form: after the IPO recapitalization, without Community Living and without the settlement. Earlier years describe a smaller, differently financed company. The first half of 2026 confirms the level is holding and rising. Operating profit from continuing operations was $252 million, against $99 million a year earlier, with two consecutive strong quarters ($121 million and $130 million). Stock compensation also fell sharply. Cash from operations in that half-year looks weak ($167 million), but the reason is known. It includes about $157 million of income taxes, far above the usual level and consistent with tax on the Community Living sale gain, plus working-capital build. Neither is a change in earning power. Cash earnings grew about 60% in 2025. For the coming year we assume about 18%, to roughly $470 million before lenders. That is well below last year's rate and close to what the first-half 2026 results already show, with a full tax bill now that interest costs are lower. Base case ($30.08 per share). The business holds its 2026 level of about $470 million and grows about 1% a year for ten years. That growth comes from the steady, self-funded opening of new locations (seven de novo offices in 2025) and adds little. After year ten the earnings hold flat. Pharmacy dispensing to long-term-care residents and home-based care for seniors are long-standing needs this company and its predecessors have served for decades. We do not credit continued rapid specialty-pharmacy growth, market expansion from an aging population, or new drug launches. None of these is contracted, and the manufacturers that supply specialty drugs can generally cancel their agreements on short notice. The business is worth about $8.39 billion. It owes about $1.76 billion net: roughly $2.19 billion of term debt and $20 million of finance leases, less about $460 million of cash beyond operating needs left from the sale proceeds. That leaves about $6.63 billion, or $30.08 per share on 220.3 million diluted shares. Bear case ($14.90 per share). This case uses risks the filings name. Price caps on the first ten negotiated Medicare Part D drugs began January 1, 2026, with more to follow, reducing revenue per prescription. Pharmacy gross margins are already sliding (8.5% to 8.2% in 2025). Specialty drug supply agreements can be cancelled on short notice. Home health and hospice depend on annual Medicare rate decisions. The company also faces several open whistleblower suits, and the Silver case set a $120 million precedent. In this case the 2026 gains partly reverse to about $380 million, earnings then fall 5% a year for four years and 1% a year after that to about $294 million, and a second $120 million settlement is paid in year three. The business is worth about $5.04 billion, owes $1.76 billion net, and leaves $3.28 billion, or $14.90 per share. Even here cash earnings cover interest roughly twice, so the term loan due February 2031 should be refinanceable. Bull case ($46.71 per share). The drivers the company has already shown keep working: specialty and infusion volume growth, and overhead growing slower than revenue (pharmacy SG&A rose 8.6% against 30.7% pharmacy revenue growth in 2025). Starting from about $520 million, which continues the first-to-second-quarter 2026 momentum, cash earnings grow 8% for two years and then taper to 2% by year ten, reaching about $775 million. They hold flat after that. The business is worth about $12.05 billion, owes $1.76 billion net, and leaves $10.29 billion, or $46.71 per share. Debt. The main borrowing is a first-lien term loan at SOFR plus 2.50%, maturing February 21, 2031, with a revolver due June 2028. At last report it traded near face value. Cash interest runs at roughly 6 to 6.5%, close to our 6% discount rate, so no adjustment for cost of debt was made. Tangible equity units issued at the IPO settle into shares by February 1, 2027 and are reflected in the diluted share count used. What could make this wrong. Specialty pharmacy now makes up about 70% of revenue at thin margins, so losing a major drug manufacturer relationship would cut deeper than the bear case assumes. The opposite risk is that our base case ignores growth the company has actually delivered for three years, and the true value is closer to the bull case. We could not review the mid-2026 quarterly report text. We therefore could not confirm whether the roughly $550 million of cash held at June 30, 2026 has since gone to debt repayment, which would not change value, or to acquisitions, which would need to earn their keep. Full 2026 working-capital detail was also unavailable.